Beleave

Canada’s Next Medical Marijuana Licensed Producer

Overview

Beleave Inc. (CSE:BE) is a Canadian biotech company and an authorized licensed producer of medical-grade cannabis under Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR). The company’s larger strategy is to obtain cultivation and sales licenses and build out North American and European distribution channels. Beleave then hopes to expand production and capitalize on expected demand-growth spurred by cannabis legalization across Canada and in select US states.

In May 2017, Beleave announced its wholly-owned subsidiary, First Access Medical, received a license to cultivate medical cannabis pursuant to the ACMPR.

“We are ecstatic to have achieved our goal of becoming a licensed producer,” said Beleave CEO Roger Ferreira. “We have remained diligent and focused throughout the process and understand that this is just the beginning of a much bigger plan and vision for Beleave.”

The company has swung into production at its 14,500-square foot First Access Medical facility, located near Hamilton, Ontario, and is expanding cultivation. Beleave is currently adding a 66,000 square-foot hybrid greenhouse to its existing site and has plans for a second separate 200,000 square-foot facility.

Beleave’s second focus is on R&D of proprietary cannabis extracts that can be used in the therapeutic treatment of a wide-range of illnesses. This branch of the business vertically integrates well with the company’s cultivation operation. Beleave has partnered with a leading research team at Ryerson University to extract and isolate unique cannabis compounds which will be evaluated under clinical trials for safety and efficacy.

In an effort to build a top-tier medical marijuana company, Beleave has assembled a renowned team of experts across different fields, each with a strategic role in propelling the company forward. Beleave considers its team as its greatest asset and a distinct advantage over its peers.

Dr. Roger Ferreira is a neuroscientist whose area of research is particularly relevant to medical marijuana, specifically particular strains of medical marijuana which have the potential to not only alleviate symptoms of disease, but also reduce brain inflammation and disease progression. Chris Murphy, a member of Beleave’s Board of Directors, is also a director of Star Produce Ltd., one of Canada’s largest distributors of fresh fruit and vegetables. Murphy’s experience in logistics, food safety, greenhouse operations, and tracking systems as well as his industry connections with greenhouses, distribution networks and retailers across North America, make him an invaluable member of the Beleave team. Dr. David Naranjit has worked in the field of analytical chemistry for decades. His extensive research background and expertise in analytical chemistry applications make him an excellent choice as an Advisor to Beleave in the development of proprietary cannabis extracts.

Dana Gidlow, Head of Veteran Affairs and Community Outreach for Beleave, is President of the Toronto Police Military Veterans Association, having served in the Canadian Forces Reserve Army from 1968 to 2011 when he retired as a Lieutenant Colonel. He also served in the Toronto Police Service for 34 years and retired as a Supervisor in 2008. Gidlow’s role at Beleave also includes ensuring the facilities adhere to the highest in security standards. Paul Evanov heads Marketing and Advertising for Beleave and has extensive experience in mass media marketing. Evanov is the Executive Vice President at Evanov Radio Group, Canada’s largest independent radio broadcaster which has 2.7 million weekly listeners across 18 radio stations. Andrew Wnek, head of the Audit & Compensation Committee/Finance and Capital Markets Advisory for Beleave, has held senior finance roles with Canadian Tire Corporation including Senior Vice President, Finance and Administration in a twenty-one year career. He also served as the Chief Information Officer for Canadian Tire for over seven years.

 

Beleave Highlights

  • ACMPR license to cultivate medical cannabis.
  • Near-term production with license in pre license inspection.
  • Production facility (14,500 square feet) complete with a capacity of 550,000 grams of marijuana per year.
  • Low-cost expansion planned including a new 66,000 square foot hybrid greenhouse operation.
  • Endorsement by the city of Hamilton.
  • Strategically appointed team of respected industry professionals across a wide range of fields.
  • Vertically integrated business including medical-grade marijuana production and the development of proprietary therapeutic extracts.
  • Actively working towards patents on extraction techniques with clinical trials to follow.
  • Tight share structure.